

The 24th Annual Maryland State Council on Cancer Control Cancer Conference
Wednesday, November 15, 2017
Speaker Biographies

Michael Carducci, MD, FACP, FASCO

Dr. Michael Carducci is the AEGON Professor in Prostate Cancer Research and the Associate Director for Clinical Research at the Hopkins Kimmel Cancer Center. He is also the Oncology Research Director for the National Capital Region. His lab and clinical research focus on the evaluation of new therapies for urologic cancers, primarily prostate cancer. Dr. Carducci has received the Michael Christian Award for Oncology Drug Development for his work. He is a member of the Miller-Coulson Academy of Clinical Excellence. He is the Chair of the GU Oncology Committee of ECOG-ACRIN, a member of the GU Steering Committee, and Co-Chair of the Investigational Drug Steering Committee for the National Cancer Institute (NCI), as well as the Associate Editor for GU Cancers for the *Journal of Clinical Oncology*.

Kenneth R. Cooke, MD

Dr. Kenneth Cooke is the Director of the Johns Hopkins Kimmel Cancer Center's Pediatric Bone Marrow Transplantation Program, as well as Herman and Walter Samuelson Professor of Oncology. Prior to his appointment at Johns Hopkins, Dr. Cooke headed the Pediatric Blood and Marrow Transplantation Program at Rainbow Babies and Children's Hospital, and University Hospitals Case Medical Center, in Cleveland, Ohio. He also co-directed the Hematologic Disorders Program of the Case Comprehensive Cancer Center at Case Western Reserve University. Dr. Cooke's research interests include inflammatory mechanisms responsible for endothelial activation and injury after allogeneic bone marrow transplants, soluble and cellular effector mechanisms that contribute to non-infection lung injury and graft-versus-host disease in both the acute and chronic settings.

A nationally recognized transplantation immunology expert, Dr. Cooke focuses primarily on new strategies to prevent and treat graft-versus-host disease and lung complications following blood and bone marrow transplantation. His research efforts have been recognized by the Leukemia and Lymphoma Society and the American Society of Clinical Investigation.

Kevin J. Cullen, MD

Dr. Kevin Cullen is the Director of the University of Maryland, Marlene and Stewart Greenebaum Comprehensive Cancer Center. Dr. Cullen, who specializes in head and neck cancer, is also a Professor of Medicine at the University of Maryland School of Medicine and is head of its program in Oncology. He joined the University of Maryland in January 2004.

A graduate of Dartmouth College and Harvard Medical School, Dr. Cullen completed his internship and residency at Beth Israel Hospital in Boston and received additional training at the NCI. He served as the Interim Director of the Lombardi Cancer Center at Georgetown University from October 2000 to September 2002 and was Professor of Medicine, Oncology and Otolaryngology at Georgetown University School of Medicine.

Dr. Cullen's research interests include cellular factors that promote the growth of cancer and molecular mechanisms that make some cancers resistant to treatment with chemotherapy. He is the author of numerous journal publications and has served on review panels for the National

Cancer Institute, the Veterans Administration Research Program, and other organizations. His honors include a special achievement award from the NCI. Outside of the University of Maryland, Dr. Cullen serves on the external advisory boards of several NCI designated cancer centers. He has chaired two working groups for the NCI and is a member of the national board of directors of the American Cancer Society and will be the chair of the board in 2018. In 2011 Dr. Cullen was appointed by President Barack Obama to the National Cancer Advisory Board.

Danielle Doberman, MD, MPH, HMDC

Dr. Doberman is the Medical Director of Palliative Medicine at Johns Hopkins Hospital, as well as a practicing clinician in Baltimore, MD, with over a decade of specialized experience in Hospice and Palliative Medicine. She oversees the clinical activity of a team of seventeen dedicated to the care of patients in both the Weinberg Cancer pavilion, and the main hospital. As a member of Gilchrist Services from 2007-2012, she was the founding Medical Director for the palliative medicine programs at both Greater Baltimore Medical Center and Howard County General Hospital. She later moved to George Washington University Hospital, where her leadership doubled the program size, both in staffing, patients served, and medical learners supervised. Dr. Doberman served as a fellow in Geriatric Medicine at the Johns Hopkins University School of Medicine, and in Hospice and Palliative Medicine at the George Washington University School of Medicine and Health Sciences, where she also earned her medical degree. She has special interests in medical education and health care planning for those with dementia.

Alexandra Gubin, MSW, LCSW-C

Ms. Alexandra Gubin serves as the Ulman Cancer Fund Young Adult Patient Navigator at Johns Hopkins Kimmel Cancer Center. Ms. Gubin works in conjunction with the Ulman Cancer Fund for Young Adults and a multidisciplinary team of healthcare professionals at the Charlotte R. Bloomberg Children's Center within the pediatric oncology division at the Kimmel Center to improve the cancer experience for young adults and to address the unique needs of young adult patients and their families. She provides resources and counseling designed to empower young adult patients and their families to take an active role in their cancer experience and supports them as they face the challenges of a cancer diagnosis.

Elizabeth A. Platz, ScD, MPH

Dr. Elizabeth Platz, is a Professor, Martin D. Abeloff, MD Scholar in Cancer Prevention, and Deputy Chair of the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health, where she directs the NCI-funded (T32) training program in Cancer Epidemiology, Prevention, and Control. She also co-leads the Cancer Prevention and Control Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and holds joint appointments in the Department of Oncology, and the Department of Urology and the James Buchanan Brady Urological Institute at the Johns Hopkins University School of Medicine.

Dr. Platz received her doctorate in epidemiology from and was a post-doctoral fellow at the Harvard School of Public Health. A major focus of her work is the use of molecular and genetic epidemiology approaches to understand the mechanisms underlying prostate incidence and progression. She conducts her work with an eye toward translation of findings into prevention and treatment strategies. Known for her leadership of multidisciplinary prostate cancer research teams, she is at the forefront of epidemiologic research on the role of inflammation, a target for

prevention, in the development of prostate cancer, and on telomere length as a prognostic marker for poor outcome after treatment for prostate cancer. She is the Principal Investigator of an NCI-funded U01 study to enhance the infrastructure of the ARIC cohort for cancer epidemiology research and NCI and Department of Defense-funded grants investigating tissue-based biomarkers of prostate cancer risk and prognosis. In addition to her academic efforts, she is the chair of the Maryland Cancer Collaborative, the group charged with prioritizing and implementing strategies from the Maryland Comprehensive Cancer Control Plan.

Victor Velculescu, MD, PhD

Dr. Victor Velculescu is the Co-Director of Cancer Biology and Professor of Oncology and Pathology at the Johns Hopkins University Kimmel Cancer Center. He is internationally known for his genomic discoveries in human cancer. Dr. Velculescu developed SAGE (serial analysis of gene expression) and used this method to perform the first transcriptome analysis in eukaryotic cells. Subsequently, he developed Digital Karyotyping for analysis of structural genomic alterations and together with his colleagues performed the first sequence analysis of the coding genome in human cancers, including breast, colorectal, brain, pancreatic, and ovarian cancers. These analyses identified a variety of genes not previously known to be involved in neoplasia, including PIK3CA gene as one of the most highly mutated genes in human cancer. More recently, his group has developed PARE (personalized analysis of rearranged ends) for non-invasive liquid biopsy approaches for tumor detection and monitoring. These discoveries provide insights into the mechanistic features and pathways underlying human cancer and provide new opportunities for individualized diagnostic and therapeutic approaches.

Dr. Velculescu completed his B.S. at Stanford University and his M.D., Ph.D., and postdoctoral fellowship in oncology at Johns Hopkins University. Dr. Velculescu is a member of the Board of Directors of American Association of Cancer Research (AACR), has served as a member of scientific advisory boards of Basser Research Center at University of Pennsylvania, the Starr Cancer Consortium, Quintiles, Helicos Biosciences, Inostics, and SoftGenetics, and is a co-founder of Personal Genome Diagnostics. He is the recipient of several awards for his work, including the Grand Prize Winner of the Amersham/Pharmacia & Science Young Scientist Prize (1999), Judson Daland Prize of the American Philosophical Society (2008), the European Association of Cancer Research and Carcinogenesis Young Investigator Award (2008), the AACR Award for Outstanding Achievement in Cancer Research (2009), the Paul Marks Prize for Cancer Research (2011), and the AACR Team Science Awards for Pancreatic (2013) and Brain Cancer Research (2014).

Lori Wiener, PhD, DCSW, LCSW-C

Dr. Lori Wiener is the co-director of the Behavioral Health Core and Head of the Psychosocial Support and Research Program at the pediatric oncology branch of the NCI. As both a clinician and behavioral scientist, Dr. Wiener has dedicated her career to the fields of oncology and pediatric HIV/AIDS. At NCI, she developed a robust clinical and research program that has focused on critical clinical issues such as lone parenting, transnational parenting, emotional consequences of medically required isolation, preparation for amputation and sibling donation, graph-versus-host disease, and adolescent end-of-life planning. Dr. Wiener has also dedicated a substantial part of her career to applying knowledge from her clinical experience and psychosocial studies to create innovative resources such as workbooks, therapeutic games and an advance care planning guide for adolescents and young adults. These resources are distributed worldwide and widely utilized in cancer centers. Dr. Wiener has published extensively, and co-edited the *Pediatric Psycho-*

Oncology: A Quick Reference on the Psychosocial Dimensions of Cancer Symptom Management, and Pediatric Psychosocial Oncology: Textbook for Multi-disciplinary Care. She has been part of the leadership team that has developed the first evidence-based psychosocial standards of care for children with cancer and their family members.

Eleanor Wilson, MD, MHS

Dr. Eleanor Wilson, a native of Louisville, Kentucky, attended medical school at Johns Hopkins Medical Institute. She completed residency training in internal medicine at Vanderbilt University Medical Center in Nashville, Tennessee, and subspecialty fellowship training in infectious disease at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland. She obtained her Masters in Clinical Research as part of a collaborative program between Duke University and the National Institutes of Health.

Dr. Wilson's scientific interests and investigations have focused on the alterations to innate and adaptive immunity in chronic viral infections, including HIV and viral hepatitis. Dr. Wilson has developed expertise in the translational research techniques beginning in medical school with Dr. Robert Siliciano, investigating HIV persistence in latently infected T-cell subsets, as well as extending through her fellowship research with Dr. Irim Sereti regarding the mechanisms connecting soluble and cellular immune activation with clinical outcomes in HIV. She is now working with Dr. Shyam Kottlil on the reconstitution of innate and adaptive immunology following clearance of Hepatitis C virus. Dr. Wilson has contributed to multiple clinical trials as a PI and Lead Associate Investigator at the National Institute of Allergy and Infectious Diseases, and is now Assistant Professor at the University of Maryland's Institute of Human Virology, working on ways to improve the health of patients with chronic viral infections and advanced liver disease.

Brock Yetso, President & CEO

Mr. Brock Yetso is the President and CEO of the Ulman Cancer Fund for Young Adults. Mr. Yetso has been involved with the Ulman Cancer Fund since its inception, and as a board member and eventually moving into the executive leadership roles. His work has demonstrated a passion and professionalism for helping those affected by cancer and issues surrounding advocacy, fundraising and program development.

Mr. Yetso serves on many committees throughout the country and works collaboratively with many local and national organizations, including the National Action Plan for Cancer Survivorship developed by CDC & Lance Armstrong Foundation, and the LIVESTRONG Young Adult Alliance. Mr. Yetso sits on several advisory boards and has participated in the development of county, state, and national public health action plans with a focus on cancer survivorship and young adult issues. He also regularly makes presentations to a variety of audiences on the key issues affecting young adults and cancer. Mr. Yetso graduated from the University of Virginia in 1999 with a BA in Economics, and from Loyola University of Maryland with an MBA in 2016.